ALSUntangled #71: Nuedexta

References

• Choi DW. Dextrorphan and dextromethorphan attenuate glutamate neurotoxicity. Brain Res. 1987; 403:333–6.
   PubMed Web of Science ®Google Scholar
• Musacchio JM, Klein M, Paturzo JJ. Effects of dextromethorphan site ligands and allosteric modifiers on the binding of (+)-[3H]3-(-3-hydroxyphenyl)-N-(1-propyl)piperidine. Mol Pharmacol. 1989; 35 :1–5.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Britto MR, Valderhaug KL, Wedlund PJ, Smith RA. Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. Clin Pharmacol Ther. 1992; 51:647–55.
   PubMed Web of Science ®Google Scholar
• Nguyen L, Thomas KL, Lucke-Wold BP, Cavendish JZ, Crowe MS, Matsumoto RR, et al. Dextromethorphan: an update on its utility for neurological and neuropsychiatric disorders. Pharmacol Ther. 2016; 159:1–22.
   PubMed Web of Science ®Google Scholar
• Gundlach AL, Largent BL, Snyder SH. Autoradiographic localization of sigma receptor binding sites in guinea pig and rat central nervous system with (+)3H-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine. J Neurosci. 1986; 6:1757–70.
   PubMed Web of Science ®Google Scholar
• Mavlyutov TA, Epstein ML, Andersen KA, Ziskind-Conhaim L, Ruoho AE. The sigma-1 receptor is enriched in postsynaptic sites of C-terminals in mouse motoneurons. An anatomical and behavioral study. Neuroscience 2010; 167:247–55.
   PubMed Web of Science ®Google Scholar
• Berry JD, Shefner JM, Conwit R, Schoenfeld D, Keroack M, Felsenstein D, et al. Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLOS One. 2013; 8:e61177.
   PubMed Web of Science ®Google Scholar
• Hayashi T, Su TP. Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. Cell 2007; 131: 596–610.
   PubMed Web of Science ®Google Scholar
• Ha Y, Dun Y, Thangaraju M, Duplantier J, Dong Z, Liu K, et al. Sigma receptor 1 modulates endoplasmic reticulum stress in retinal neurons. Invest Ophthalmol Vis Sci. 2011; 52: 527–40.
   PubMed Web of Science ®Google Scholar
• Meunier J, Hayashi T. Sigma-1 receptors regulate Bcl-2 expression by reactive oxygen species-dependent transcriptional regulation of nuclear factor kappaB. J Pharmacol Exp Ther. 2010; 332: 388–97.
   PubMed Web of Science ®Google Scholar
• Lobner D, Lipton P. Sigma-ligands and non-competitive NMDA antagonists inhibit glutamate release during cerebral ischemia. Neurosci Lett. 1990; 117:169–74.
   PubMed Web of Science ®Google Scholar
• Balasuriya D, Stewart AP, Edwardson JM. The σ-1 receptor interacts directly with GluN1 but not GluN2A in the GluN1/GluN2A NMDA receptor. J Neurosci. 2013; 33:18219–24.
   PubMed Web of Science ®Google Scholar
• Zhang X-J, Liu L-L, Jiang S-X, Zhong Y-M, Yang X-L. Activation of the ζ receptor 1 suppresses NMDA responses in rat retinal ganglion cells. Neuroscience 2011; 177:12–22.
   PubMed Web of Science ®Google Scholar
• Mancuso R, Oliván S, Rando A, Casas C, Osta R, Navarro X, et al. Sigma-1R agonist improves motor function and motoneuron survival in ALS mice. Neurotherapeutics. 2012; 9:814–26.
   PubMed Web of Science ®Google Scholar
• Peviani M, Salvaneschi E, Bontempi L, Petese A, Manzo A, Rossi D, et al. Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation. Neurobiol Dis. 2014; 62:218–32.
   PubMed Web of Science ®Google Scholar
• Mavlyutov TA, Guo L-W, Epstein ML, Ruoho AE. Role of the Sigma-1 receptor in amyotrophic lateral sclerosis (ALS). J Pharmacol Sci. 2015; 127:10–6.
   PubMed Web of Science ®Google Scholar
• Ono Y, Tanaka H, Takata M, Nagahara Y, Noda Y, Tsuruma K, et al. SA4503, a sigma-1 receptor agonist, suppresses motor neuron damage in in vitro and in vivo amyotrophic lateral sclerosis models. Neurosci Lett. 2014; 559:174–8.
   PubMed Web of Science ®Google Scholar
• DeCoster MA, Klette KL, Knight ES, Tortella FC. Sigma receptor-mediated neuroprotection against glutamate toxicity in primary rat neuronal cultures. Brain Res. 1995; 671:45–53.
   PubMed Web of Science ®Google Scholar
• Liu Y, Qin L, Li G, Zhang W, An L, Liu B, et al. Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J Pharmacol Exp Ther. 2003; 305:212–8.
   PubMed Web of Science ®Google Scholar
• Zhang W, Wang T, Qin L, Gao H-M, Wilson B, Ali SF, et al. Neuroprotective effect of dextromethorphan in the MPTP Parkinson’s disease model: role of NADPH oxidase. Faseb J. 2004; 18: 589–91.
   PubMed Web of Science ®Google Scholar
• Shah NS, et al. Dextromethorphan-Quinidine (Nuedexta) improves swallowing in Bulbar onset ALS patients with pseudobulbar affect - pre-post observational study in 86 ALS patients (P4.4-019). Neurology 2019; 92:P4.4–019.
   Web of Science ®Google Scholar
• Sancho J, Ferrer S, Burés E, Luis Díaz J, Torrecilla T, Signes-Costa J, et al. Effect of one-year dextromethorphan/quinidine treatment on management of respiratory impairment in amyotrophic lateral sclerosis. Respir Med. 2021; 186:106536.
   PubMed Web of Science ®Google Scholar
• Smith R, Pioro E, Myers K, Sirdofsky M, Goslin K, Meekins G, et al. Enhanced bulbar function in amyotrophic lateral sclerosis: the nuedexta treatment trial. Neurotherapeutics. 2017; 14:762–72.
   PubMed Web of Science ®Google Scholar
• Smith RA, Macklin EA, Myers KJ, Pattee GL, Goslin KL, Meekins GD, et al. Assessment of bulbar function in amyotrophic lateral sclerosis: validation of a self-report scale (center for neurologic study bulbar function scale). Eur J Neurol. 2018; 25:907–e66.
   PubMed Web of Science ®Google Scholar
• Proceedings of the 21st Annual Meeting of the Northeast ALS Consortium. Muscle & Nerve, 2022; 66(S2): S1–S63.
   Google Scholar
• Pattee GL, Wymer JP, Lomen-Hoerth C, Appel SH, Formella AE, Pope LE, et al. An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions. Curr Med Res Opin. 2014; 30:255–65.
   Web of Science ®Google Scholar
• Brooks BR, Thisted RA, Appel SH, Bradley WG, Olney RK, Berg JE, et al. Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial. Neurology 2004; 63:1364–70.
   PubMed Web of Science ®Google Scholar
• Pioro EP, Brooks BR, Cummings J, Schiffer R, Thisted RA, Wynn D, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010; 68:693–702.
   PubMed Web of Science ®Google Scholar